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Introduction
Recent hypothesis-generating studies have sparked new 
interest in an old concept: adjuvant vitamin therapy in 
critical illness or “metabolic resuscitation”. In this mini-
review, we report on the most promising players in this 
setting: thiamine (vitamin B1), vitamin C, and vitamin D. 
Their main characteristics are summarized in Table 1 (see 
also electronic supplementary material, ESM).
Thiamine
Function
Thiamine is the precursor of thiamine pyrophosphate 
(TPP), the essential coenzyme of several decarboxylases 
required for glucose metabolism, the Krebs cycle, the 
generation of ATP, the pentose phosphate pathway, and 
the production of NADPH [1, 2].
Thiamine and acute illness
Apart from lactic acidosis due to failure of pyruvate to 
enter the Krebs cycle, two potentially fatal deficiency 
conditions are known: cardiac (or wet) beriberi, and 
Gayet–Wernicke encephalopathy. Thiamine deficiency 
was first described in critically ill patients in the 1980s 
and is recognized as being associated with mortality [2]. 
Hypermetabolic states and parenteral nutrition without 
micronutrients predispose to acute deficiency of thia-
mine [1]. Thiamine deficiency is present in 20–70% of 
septic shock patients, depending on the cutoff value used 
[2]. Analytical issues associated with TPP determination 
in inflammation complicate the diagnosis of deficiency. 
High-performance liquid chromatography (HPLC) on 
whole blood together with erythrocyte determination 
represents the most reliable method (ESM).
Dose and future
Preventive interventions have shown controversial 
results. A randomized trial using a single dose of 300 mg 
thiamine versus placebo before elective cardiac surgery 
[3] normalized plasma thiamine without affecting post-
operative lactate concentrations.
In contrast, the metabolic effects of thiamine justify 
further investigations in sepsis. A randomized trial con-
ducted in 88 septic shock patients (2 × 200 mg thiamine/
day for 7 days) showed decreasing lactate levels. A signifi-
cant difference in time to death was observed in favor of 
thiamine (P = 0.047), with lower mortality (13 versus 46% 
in controls) in the subgroup of patients with deficiency 
[4]. The post hoc analysis showed that the thiamine group 
had lower creatinine levels with less progression to renal 
replacement therapy than the placebo group [5]. In a 
highly controversial, small before–after trial, a combina-
tion of thiamine, hydrocortisone, and vitamin C in sepsis 
was associated with a large reduction of organ dysfunc-
tion [6]; this finding requires validation. In view of the 
current evidence, the low risks, and the low costs, admin-
istration of liberal amounts of thiamine (300 mg I.V. daily 
in at-risk patients and 100 mg in all other patients during 
the first 48 h in the ICU) should be considered as it ena-
bles metabolic handling of dextrose 5%.
Vitamin C
Vitamin C (ascorbate) has pleiotropic effects. During 
critical illness, acute deficiency of vitamin C is com-
mon (eTable  2, ESM) but generally goes unnoticed 
because the symptoms mimic critical illness and rapid 
measurement of plasma concentrations is not available. 
Acute vitamin C deficiency may contribute to hypo-
tension, exaggerated inflammation, capillary leakage, 
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microcirculatory compromise, oxidative organ injury, 
and impaired immune defense and wound healing.
Function
Vitamin C is an electron donor, which accounts for its 
myriad functions [7]. It is cofactor/cosubstrate for the 
biosynthesis of neurotransmitters (noradrenaline, sero-
tonin), cortisol, peptide hormones (vasopressin), and 
collagen. Vitamin C is the most potent water-soluble 
antioxidant. It directly scavenges radicals and recycles 
other antioxidants, and protects the endothelium by pro-
moting collagen synthesis and maintaining endothelial 
vasodilation and barrier function [8]. Vitamin C can limit 
the inflammatory response and ischemia–reperfusion 
injury, improve host defense, wound healing, and mood, 
and reduce pain (ESM).
Vitamin C and acute illness
Critical illness abruptly increases vitamin C requirements 
(ESM). Activated neutrophils accumulate vitamin C, 
while the adrenals secrete accumulated vitamin C, trig-
gering cortisol production [7]. Although redistributed, 
vitamin C is likely lost during cell degradation. Further-
more, while some of the oxidized vitamin C is normally 
recycled, some is lost if reducing mechanisms fail [7]. 
Additionally, vitamin C is consumed during the synthesis 
of norepinephrine, peptide hormones, and cortisol.
Dose and future
The optimal dose and plasma concentration of vitamin C 
remain unknown. Several trials (eTable  2, ESM) using a 
repletion dose (0.5–3 g/day) reported improved recovery 
from organ failure [8]. The results of recent preliminary 
trials (eTable 3, ESM) suggest that a short course of phar-
macological doses in severe sepsis (50–200  mg/kg/day 
or 6 g/day with or without hydrocortisone and thiamine 
[6]) reduces vasopressor dose and promotes recovery, but 
the tendency towards lower mortality needs confirma-
tion (eTable 3, ESM) [6, 9, 10]. High doses seem to be safe 
(ESM). Pathophysiological findings suggest that pharma-
cological doses of intravenous vitamin C should probably 
be limited to the early phase, because low levels of radi-
cals are crucial for (intra)cellular signaling.
Vitamin D
Humans can produce vitamin D endogenously under 
conditions of sufficient UVB exposure. Vitamin D is a 
precursor to a steroid hormone with a specific nuclear 
receptor (vitamin D receptor) present in a variety of dif-
ferent cell types and organs.
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Function
Vitamin D acts via pleiotropic, cell-specific genomic and 
nongenomic pathways [11]. Target organs that are par-
ticularly relevant in the ICU include muscle, lung, heart, 
immune system, and kidney. In contrast to vitamin C and 
thiamine, testing for vitamin D is fast, widely available, 
and sufficiently reliable.
Vitamin D and acute illness
Depending on definition and population, vitamin D defi-
ciency [usually defined as serum 25(OH)D ≤ 20  ng/ml] 
is present in 30–60% of ICU patients worldwide. Since 
2009, observational studies have clearly shown that vita-
min D deficiency is linked to excess morbidity and mor-
tality in adults and children in the ICU [12]. Preliminary 
data using novel methods suggest that glutathione and 
glutamate pathway metabolism, which are important for 
redox regulation and immunomodulation, are affected by 
vitamin D status [13].
So far, worldwide < 700 patients have been treated for 
vitamin D deficiency in a very limited number of rand-
omized controlled intervention trials, recently summa-
rized in different meta-analyses [14]. The VITdAL-ICU 
study (n = 475) did not find a difference in the length of 
hospital stay between groups, but there was a significant 
reduction in mortality in the predefined subgroup of 
patients with severe vitamin D deficiency [15]. The most 
recent meta-analysis concludes that vitamin D in the ICU 
may be associated with mortality reduction [12].
Dose and future
The optimal native vitamin D dose in critical illness is 
unknown, but up to 10,000  IU daily is considered safe; 
the standard dose of 600–800  IU, however, is ineffec-
tive in the acute setting. The logical question, “Can vita-
min D supplementation during or before critical illness 
improve outcomes?”, is currently the subject of intensive 
research aiming to include > 5000 patients in the VIO-
LET study (NCT03096314) and the VITDALIZE study 
(NCT03188796).
Summary, conclusions and outlook
Vitamin C, vitamin D, and thiamine are promising 
micronutrients for adjuvant therapy in severe acute ill-
ness. We recommend early supplementation to prevent/
treat deficiency (Table 1). Due to increased needs, criti-
cally ill patients need amounts higher than the daily rec-
ommended dose, but pharmacological dosing requires 
further studies (ESM).
Important considerations include the following:
  • The requirements for vitamin C, vitamin D, and thia-
mine are likely higher in severe illness than in health 
(ESM).
  • The beneficial effect on clinical outcomes will be 
greater in depleted subjects.
  • Determination of thiamine and vitamin C deficiency 
is not possible without major delay and may be inval-
idated by improper sampling.
  • A better understanding of the role of micronutrients 
in critical illness may be achievable by means of novel 
methods including genomics and metabolomics.
  • The time is ripe for pragmatic randomized trials 
in different high-risk populations exhibiting over-
whelming oxidative stress using different treatment 
regimes.
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